Vera Therapeutics, Inc. (NASDAQ:VERA) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. boosted its position in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 71.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 221,485 shares of the company's stock after purchasing an additional 92,390 shares during the period. JPMorgan Chase & Co. owned about 0.35% of Vera Therapeutics worth $9,367,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in shares of Vera Therapeutics by 14.3% in the 4th quarter. Vanguard Group Inc. now owns 2,949,564 shares of the company's stock worth $124,737,000 after acquiring an additional 369,387 shares during the period. Jennison Associates LLC raised its holdings in Vera Therapeutics by 82.0% during the fourth quarter. Jennison Associates LLC now owns 813,861 shares of the company's stock worth $34,418,000 after purchasing an additional 366,763 shares during the last quarter. Victory Capital Management Inc. boosted its position in Vera Therapeutics by 515.0% during the fourth quarter. Victory Capital Management Inc. now owns 235,267 shares of the company's stock worth $9,949,000 after purchasing an additional 197,014 shares in the last quarter. Lord Abbett & CO. LLC grew its holdings in Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after purchasing an additional 124,197 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Vera Therapeutics in the fourth quarter valued at $2,948,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on VERA shares. JPMorgan Chase & Co. decreased their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a research report on Tuesday, March 4th. The Goldman Sachs Group started coverage on shares of Vera Therapeutics in a report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target on the stock. Guggenheim raised their price target on Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. Finally, Wolfe Research started coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 target price on the stock. One research analyst has rated the stock with a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Stock Up 0.2 %

Shares of NASDAQ VERA traded up $0.05 during trading on Friday, reaching $21.29. 661,231 shares of the stock were exchanged, compared to its average volume of 747,566. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $51.61. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -8.16 and a beta of 1.28. The company has a quick ratio of 13.76, a current ratio of 13.76 and a debt-to-equity ratio of 0.17. The business's 50-day moving average price is $26.09 and its 200 day moving average price is $36.50.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last issued its quarterly earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, beating analysts' consensus estimates of ($0.83) by $0.11. As a group, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.